Creating a living biobank of lung cancer organoids
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)
The University of Texas Health Science Center at San Antonio · NCT03655015
This study is trying to create a collection of lung cancer samples from patients to help with future research and understand more about the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Texas Health Science Center at San Antonio (other) |
| Locations | 1 site (San Antonio, Texas) |
| Trial ID | NCT03655015 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a living biobank of patient-derived organoids (PDOs) from individuals diagnosed with Stage I-IV lung cancer. By enrolling at least 50 patients, the researchers will collect tumor specimens during surgery and culture these organoids for future experiments. The study will also analyze circulating tumor cells (CTCs) and gather patient demographic information, treatment history, and survival data through questionnaires. No specific treatment will be provided as part of this observational study.
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 and older with a diagnosis of lung cancer or related conditions who are undergoing standard treatment.
Not a fit: Patients who are not undergoing tumor resection or systemic treatment as part of their standard care may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lung cancer treatment responses and improve personalized treatment strategies.
How similar studies have performed: Other studies utilizing patient-derived organoids have shown promise in understanding cancer biology and treatment responses, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history Exclusion Criteria: * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
Where this trial is running
San Antonio, Texas
- UT Health San Antonio, M.D. Anderson Cancer Center — San Antonio, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Josephine Taverna, MD — UT Health San Antonio M.D. Anderson Cancer Center
- Study coordinator: Josephine Taverna, MD
- Email: tavernaj@uthscsa.edu
- Phone: 210-450-8234
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Neoplasm